抄録
The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR-237 G: 3.0 g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as 'moderately improved' or more were 59.1% (13/22) and 68.2% (15/22), respectively. The rates in the final global improvement was 68.2% (15/22). The rates in the diarrhea and constipation predominant cases were 66.7% (12/18) and 75.0% (3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0% (1/25), which was slightly and not serious. The rate of the cases assessed as 'no problem in safety' in the overall safety rating was 96.0% (24/25). In the global utility rating, the rate of cases assessed as 'useful' or more was 63.6% (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.
| 元の言語 | English |
|---|---|
| ページ（範囲） | 219-232 |
| ページ数 | 14 |
| ジャーナル | Japanese Pharmacology and Therapeutics |
| 巻 | 26 |
| 発行部数 | SUPPL. 5 |
| 出版物ステータス | Published - 1998 |
| 外部発表 | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
これを引用
Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome. / Wada, T.; Yoshikawa, Y.; Yahagi, Naohisa; Kawamura, N.; Kakei, N.; Matsubara, Y.; Tsuji, M.; Miki, K.
：: Japanese Pharmacology and Therapeutics, 巻 26, 番号 SUPPL. 5, 1998, p. 219-232.研究成果: Article
}
TY - JOUR
T1 - Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome
AU - Wada, T.
AU - Yoshikawa, Y.
AU - Yahagi, Naohisa
AU - Kawamura, N.
AU - Kakei, N.
AU - Matsubara, Y.
AU - Tsuji, M.
AU - Miki, K.
PY - 1998
Y1 - 1998
N2 - The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR-237 G: 3.0 g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as 'moderately improved' or more were 59.1% (13/22) and 68.2% (15/22), respectively. The rates in the final global improvement was 68.2% (15/22). The rates in the diarrhea and constipation predominant cases were 66.7% (12/18) and 75.0% (3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0% (1/25), which was slightly and not serious. The rate of the cases assessed as 'no problem in safety' in the overall safety rating was 96.0% (24/25). In the global utility rating, the rate of cases assessed as 'useful' or more was 63.6% (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.
AB - The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR-237 G: 3.0 g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as 'moderately improved' or more were 59.1% (13/22) and 68.2% (15/22), respectively. The rates in the final global improvement was 68.2% (15/22). The rates in the diarrhea and constipation predominant cases were 66.7% (12/18) and 75.0% (3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0% (1/25), which was slightly and not serious. The rate of the cases assessed as 'no problem in safety' in the overall safety rating was 96.0% (24/25). In the global utility rating, the rate of cases assessed as 'useful' or more was 63.6% (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.
KW - Calcium polycarbophil
KW - Constipation
KW - Diarrhea
KW - Fine granule
KW - Gastrointestinal symptoms
KW - Irritable bowel syndrome
KW - Stool disorders
UR - http://www.scopus.com/inward/record.url?scp=0031791512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031791512&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0031791512
VL - 26
SP - 219
EP - 232
JO - Japanese Pharmacology and Therapeutics
JF - Japanese Pharmacology and Therapeutics
SN - 0386-3603
IS - SUPPL. 5
ER -